GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genmab AS (CHIX:GMABc) » Definitions » Receivables Turnover

Genmab AS (CHIX:GMABC) Receivables Turnover : 0.89 (As of Sep. 2024)


View and export this data going back to 2008. Start your Free Trial

What is Genmab AS Receivables Turnover?

The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Genmab AS's Revenue for the three months ended in Sep. 2024 was kr5,540 Mil. Genmab AS's average Accounts Receivable for the three months ended in Sep. 2024 was kr6,239 Mil. Hence, Genmab AS's Receivables Turnover for the three months ended in Sep. 2024 was 0.89.


Genmab AS Receivables Turnover Historical Data

The historical data trend for Genmab AS's Receivables Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genmab AS Receivables Turnover Chart

Genmab AS Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Receivables Turnover
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.49 3.71 2.89 3.20 3.09

Genmab AS Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Receivables Turnover Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.93 0.92 0.86 1.00 0.89

Competitive Comparison of Genmab AS's Receivables Turnover

For the Biotechnology subindustry, Genmab AS's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Genmab AS's Receivables Turnover Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Genmab AS's Receivables Turnover distribution charts can be found below:

* The bar in red indicates where Genmab AS's Receivables Turnover falls into.



Genmab AS Receivables Turnover Calculation

Receivables Turnover measures the number of times a company collects its average accounts receivable balance.

Genmab AS's Receivables Turnover for the fiscal year that ended in Dec. 2023 is calculated as

Receivables Turnover (A: Dec. 2023 )
=Revenue / Average Total Inventories
=Revenue (A: Dec. 2023 ) / ((Accounts Receivable (A: Dec. 2022 ) + Accounts Receivable (A: Dec. 2023 )) / count )
=16474 / ((5712 + 4947) / 2 )
=16474 / 5329.5
=3.09

Genmab AS's Receivables Turnover for the quarter that ended in Sep. 2024 is calculated as

Receivables Turnover (Q: Sep. 2024 )
=Revenue / Average Total Inventories
=Revenue (Q: Sep. 2024 ) / ((Accounts Receivable (Q: Jun. 2024 ) + Accounts Receivable (Q: Sep. 2024 )) / count )
=5540 / ((6168 + 6310) / 2 )
=5540 / 6239
=0.89

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Genmab AS  (CHIX:GMABc) Receivables Turnover Explanation

An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.


Genmab AS Receivables Turnover Related Terms

Thank you for viewing the detailed overview of Genmab AS's Receivables Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.


Genmab AS Business Description

Address
Carl Jacobsens Vej 30, Valby, DNK, 2500
Genmab AS is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.

Genmab AS Headlines

No Headlines